Engineered Tandem Thymosin Peptide Shows Superior Corneal Wound Healing

Corneal injuries pose serious threats to vision, requiring rapid and effective healing to prevent complications like scarring and infection. Thymosin beta-4 (TB4), a naturally occurring 43-amino acid peptide, has shown promise in promoting corneal wound healing and is currently in clinical trials. However, TB4 faces significant limitations including short half-life and expensive synthesis costs that limit widespread application.

Researchers at the University of Houston engineered a novel tandem thymosin beta-4 (tTB4) by linking two TB4 molecules together. Using structural modeling with AlphaFold, they demonstrated that tTB4 can simultaneously bind and sequester two G-actin molecules, creating a larger pool of available actin for cellular reorganization compared to single TB4.

In laboratory studies using human corneal epithelial cells, tTB4 promoted greater cell viability and migration than TB4 at equivalent concentrations. The researchers then tested both peptides in a mouse model of alkali-induced corneal burns, a severe injury that mimics chemical eye injuries in humans.

The results showed tTB4 significantly outperformed TB4 in promoting corneal wound healing and reducing scarring. Mice treated with tTB4 showed faster epithelial resurfacing, reduced inflammation, and better overall corneal integrity compared to those treated with standard TB4 or control treatments.

Crucially, tTB4 can be produced through bacterial fermentation rather than expensive chemical synthesis, potentially reducing manufacturing costs substantially. The tandem design may also provide improved stability and longer half-life, addressing key limitations of current TB4 therapy. These findings suggest tandem peptide engineering could enhance other regenerative therapies while improving their economic viability for widespread clinical use.